Finally, the data about hemopoiesis improvement and NF-κB activity inhibition have the potential to provide new insight into iron chelation and its beneficial effects, all suggesting that higher risk MDS patients may also be good candidates for this therapy [66–68, 71]. This evidence concerns the gene NFKB1 and myelodysplastic syndrome.